Sanofi
USPTO PatentsView assignee record - 721 granted patents across 67 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Sanofi ranks #612 of 49,997 tracked US assignees by granted-patent volume, with 721 patents across 67 technology areas.
- #612
- of 49,997 US assignees by volume
- Top 1%
- by Innovation Score (66.5/100)
- 17.2
- avg claims per patent
- -2%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R612 · Foreign Corporation #612 · 721 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL
- GRANTS-MID 721 grants
- TOP-DECILE #612/49,997
- PHOTO-FINISH Council OF Scientifi…
- CPC-WIDE A61P · 67 areas
- INNOV-STRONG 66.5/100
- CLAIMS-RICH 17.2 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-FLAT -2% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Council OF Scientific AND Industrial Research (±1 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Sanofi’s 66.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Sanofi
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Rockwell Collins · near
Rockwell Collins · near
67 score
- Tmeic · near
Tmeic · near
67 score
- Sanofi · this assignee
Sanofi · this assignee
67 score
- Sony OF America · near
Sony OF America · near
67 score
- Thales Canada · near
Thales Canada · near
67 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Sanofi's Innovation Score is 66.5/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Sanofi?
Each dot is one of Sanofi’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sanofi’s own 17.2 claims/patent is ABOVE the 15.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
How Sanofi's grant cadence moved
Between 2020–2024, Sanofi received 319 grants versus 324 in 2015–2019 (-2% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2023 at 81 grants and bottomed in 2021 at 44. Lead class A61P accounts for 41.5% of the portfolio across 67 subclasses. Volume neighbours: TCL China Star Optoelectronics Technology Co., Ltd. (#608) and Dana-farber Cancer Institute, Inc. (#616).
Sanofi's three-year grant acceleration
From 2019–2021 to 2022–2024, Sanofi moved from 171 to 217 grants (1.27x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #684. See the growth leaderboard.
Who files at Sanofi's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- TCL China Star Op…
TCL China Star Optoelectronics Technology Co., Ltd.
728 patents
- ST Jude Medical C…
ST. Jude Medical, Cardiology Division, Inc.
727 patents
- Exxonmobil Resear…
Exxonmobil Research AND Engineering Company
724 patents
- Seoul Viosys
Seoul Viosys Co., Ltd.
723 patents
- Sanofi ◀
Sanofi
721 patents
- Council OF Scient…
Council OF Scientific AND Industrial Research
720 patents
- Hoya
Hoya Corporation
718 patents
- Roku
Roku, Inc.
717 patents
- Dana-farber Cance…
Dana-farber Cancer Institute, Inc.
716 patents
What this shows Sanofi holds 721 patents at rank #612, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Sanofi
By rank, the assignees closest to #612 in granted patent volume.
- TCL China Star Optoelectronics Technology Co., Ltd. #608 · 728 patents
- ST. Jude Medical, Cardiology Division, Inc. #609 · 727 patents
- Exxonmobil Research AND Engineering Company #610 · 724 patents
- Seoul Viosys Co., Ltd. #611 · 723 patents
- Council OF Scientific AND Industrial Research #613 · 720 patents
- Hoya Corporation #614 · 718 patents
- Roku, Inc. #615 · 717 patents
- Dana-farber Cancer Institute, Inc. #616 · 716 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Sanofi's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Sanofi, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Sanofi ranks #40 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (67 here).
Similar claim depth
Nearest assignees by average claims per patent (17.2 here).
Sanofi's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
67 Top 1% higher than 99% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 78 | 10.8% |
| 2016 | 55 | 7.6% |
| 2017 | 65 | 9.0% |
| 2018 | 57 | 7.9% |
| 2019 | 69 | 9.6% |
| 2020 | 58 | 8.0% |
| 2021 | 44 | 6.1% |
| 2022 | 57 | 7.9% |
| 2023 | 81 | 11.2% |
| 2024 | 79 | 11.0% |
| 2025partial year | 78 | 10.8% |
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Sanofi's patent record in context - here's where to go next.
- Sanofi's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 41.5% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #612 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Sanofi against TCL China Star Optoelectronics Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 66.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.